Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Sep;30(8-9):450-1.
doi: 10.1159/000105131. Epub 2007 Sep 7.

Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib

Oliver Ranze  1 , Erich Hofmann, Andrea Distelrath, Heinz-Gert Hoeffkes
Affiliations
Case Reports

Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib

Oliver Ranze et al. Onkologie. 2007 Sep.

Abstract

Background: Sorafenib has been approved in the U.S. and the European Union for patients with advanced renal cell cancer (RCC). There is evidence that treatment with sorafenib can achieve partial remissions in patients with brain metastases of RCC.

Case report: We report of a patient with leptomeningeal carcinomatosis of RCC, who 10 days after initiation of sorafenib therapy showed a noticeable decrease in contrast enhancement of the tumor in a magnetic resonance imaging (MRI) scan of the brain. This partial response was verified by an MRI scan on day 74.

Discussion: Results of a sub-evalution of a randomized phase III trial show that sorafenib offers encouraging activity in the treatment of patients with RCC and brain metastases.

Conclusion: This case shows that sorafenib can achieve rapid tumor response in a patient with leptomeningeal carcinomatosis of RCC. This partial remission can persist for at least 10 weeks.

PubMed Disclaimer

Publication types

MeSH terms